The 7.8% drop in Gentherm's share price is directly linked to the disappointing Q4 2024 results and 2025 guidance. The automotive segment's revenue decline and the small size of the medical segment contribute to the negative outlook. Despite being attractively priced, the shares are only fairly valued compared to peers, indicating limited upside potential in the short term.